Affect and Post-COVID-19 Symptoms in Daily Life

Affect and post-COVID-19 symptoms in daily life: An exploratory 1

2

experience sampling study

- 3 Gerko Schaap^{1*}, Marleen Wensink¹, Carine J. M. Doggen^{2,3}, Job van der Palen^{4,5}, Harald E.
- 4 Vonkeman^{1,6}, and Christina Bode¹
- 5
- ¹ Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands 6
- 7 ² Department of Health Technology and Services Research, Technical Medical Centre, University of
- 8 Twente, Enschede, The Netherlands
- 9 ³ Clinical Research Centre, Rijnstate Hospital, Arnhem, The Netherlands
- 10 ⁴ Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands
- 11 ⁵ Section of Cognition, Data and Education, University of Twente, Enschede, The Netherlands
- 12 ⁶ Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The
- 13 Netherlands
- 14
- 15 *Corresponding author
- 16 E-mail: g.schaap@utwente.nl (GS)
- 17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Affect and Post-COVID-19 Symptoms in Daily Life

Abstract 18

19 Insight into the daily life experiences of patients with post-COVID-19 syndrome is lacking. The 20 current study explored temporal fluctuations of and associations between positive and negative affect 21 and symptoms throughout the day in previously hospitalised post-COVID-19 patients using an 22 experience sampling methodology. Ten participants (age: median = 60, interquartile range = 9 years; 23 50% women ; $80\% \ge 1$ comorbidity; 8-12 months since hospital discharge) filled out brief online 24 questionnaires, six times a day for 14 consecutive days. Positive and negative affect, and self-reported 25 symptoms (physical and mental fatigue, cognitive functioning, dyspnoea, and pain) were assessed in 26 real-time. Primarily, graphs were analysed to assess the individual longitudinal courses of and 27 (concurrent and time-lagged) associations between affect and symptoms. Secondly, correlations or 28 multilevel linear regression models were used to support these interpretations. Visual assessment 29 showed limited temporal fluctuation in affect and symptoms. All symptoms appeared to associate 30 positively with each other (correlations between .26 and .85). Positive affect was associated with lower 31 symptoms severity (β 's between -.28 and -.67), and negative affect with higher symptoms severity (β 's 32 between .24 and .66). Time-lagged analyses showed that – adjusted for residual symptom severity of prior measurements – both types of affect predicted symptom severity two hours later (β 's between -.09 33 34 and -.31 for positive affect; between .09 and .28 for negative affect). These findings suggest that positive 35 and negative affect may play important roles in post-COVID-19 symptom experience and temporal 36 fluctuation.

37

Keywords: Post-COVID-19 syndrome; long COVID; symptoms; affect; Experience Sampling 38 39 Methodology; Ecological Momentary Assessment

Affect and Post-COVID-19 Symptoms in Daily Life

Introduction 40

41 While most people recover from a SARS-CoV-2 infection, a substantial group struggles with 42 persistent symptoms. These sequelae are often referred to as long-COVID or as post-COVID-19 43 syndrome, which can be defined as "signs and symptoms that developed during or after an infection 44 consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis" [1]. Estimated prevalence ranges between 6 to 45 percent of COVID-19 survivors [2-4], 45 46 depending on definitions, populations, vaccination status, and SARS-CoV-2 variants within these 47 samples. Most frequently reported post-COVID-19 symptoms include fatigue, cognitive dysfunction or 48 brain fog, respiratory problems such as dyspnoea (breathlessness), chronic pain, and loss of sense of 49 smell; often co-occurring [3, 5-9]. Previous research is mostly limited to cross-sectional or cohort 50 studies, and few studies looked into the severity of these symptoms, their daily fluctuations, and the 51 interrelations between these symptoms. Similarly, while reviews [6, 8] and qualitative studies [10-13] 52 reported the effects on mental health and health-related quality of life, the daily fluctuations over time 53 of positive and negative affect in post-COVID-19 patients have not vet been investigated.

54 Affect may play an important role in the severity, daily course, and potentially management of post-COVID-19 symptoms. One relevant framework to understand the associations between affect and 55 56 symptoms is the Broaden-and-Build theory of positive emotions [14, 15]. Negative emotions narrow 57 patients' attention and behaviours towards specific action tendencies necessary for survival, such as fear evoking an urge to escape [16]. In contrast, positive emotions can broaden patients' perspectives and 58 59 approaches and help build personal physical, cognitive, social and psychological resources [14]. For health, this translates into the risk for negative affect to restrict one's attention on symptoms, whereas 60 61 positive affect may help patients to find additional resources to cope with their symptoms and aid with 62 self-management in general. This relationship between affect and symptoms has been found in many 63 patient populations, and the directions of these relationships can be surprising; while it seems common 64 sense that negative affect follows from increased symptom severity, the reverse can also be true. Both 65 negative and positive affect have been found to be bidirectionally associated with or predictive of chronic symptoms such as fatigue, dyspnoea, and pain in various patient populations [17-22]. These 66

Affect and Post-COVID-19 Symptoms in Daily Life

67 studies mostly made use of cross-sectional designs and investigated these relations at a trait level or 68 relatively stable level, and hence provide little insight into short-term associations. In addition, 69 investigating whether affect informs an increase or decrease of symptom severity shortly later allows for a richer, more detailed and nuanced understanding of illness experiences on a daily level. Moreover, 70 71 this understanding may guide in identifying opportunities for more advanced interventions; advanced in 72 the sense of potential for tailoring and personalisation. Currently it is not known whether positive and 73 negative affect are predictive of post-COVID-19 symptoms, and how these are experienced real-time 74 over the day.

75 To address the gaps in current knowledge, this observational study aimed to explore the daily 76 courses of and interrelations between positive and negative affect and post-COVID-19 symptom 77 severity, such as of fatigue, cognitive dysfunction, dyspnoea, and pain. An Experience Sampling 78 Methodology (ESM) has been applied, which allowed investigating these aspects in daily life through 79 repeated real-time assessments. Moreover, this method helps overcome recall bias, and due to the repeated observations within participants, allows for rich and robust insights in patients' daily 80 81 experiences, even in small patient samples [23]. The following research questions were to assess: (1) 82 temporal fluctuations of affect and post-COVID-19 symptoms; (2) whether these symptoms were associated with (a) positive and (b) negative affect measured concurrently; and (3) whether symptoms 83 84 were predicted by (a) positive and (b) negative affect measured at an earlier timepoint using time-lagged 85 analyses.

86

Methods 87

Recruitment 88

89 This study is part of a larger, on-going cohort study on the long-term impact of severe COVID-90 19 requiring hospitalisation (registered at ClinicalTrials.gov; NCT05813574). For the present study, 91 participants were selected based on self-reported health status three months after hospital discharge and 92 their self-assessed health status at the time of recruitment. Formerly hospitalised COVID-19 patients 93 who indicated their health to be much worse compared to a year ago on the Dutch Short Form Health

perpetuity. It is made available under a CC-BY 4.0 International license.

Affect and Post-COVID-19 Symptoms in Daily Life

94 Survey (SF-36)[24] were selected for an interview [13]. During the interview, approximately 9 months 95 after hospital discharge, self-perceived health status was reassessed, and participants were screened for 96 symptoms (e.g. fatigue). If participants still suffered from post-COVID-19-associated symptoms, they 97 were invited for the present study. Out of the 16 selected candidates, 11 were willing to participate. 98 Inclusion criteria were: a) having been discharged from hospital after polymerase chain reaction-99 confirmed acute COVID-19; b) persisting, fluctuating symptoms attributed by the participant to post-100 COVID-19 syndrome; c) ≥ 18 years of age; d) proficiency in Dutch; and e) willingness to install a 101 smartphone-based measurement app. Participants were excluded from analysis in case of compliance 102 rates <30% of the daily assessments [23]. All participants provided written informed consent, and the 103 Medisch Spectrum Twente Institutional Review Board (K20-30) and the Ethics Committee Behavioural, 104 Management and Social Sciences of the University of Twente, the Netherlands (210799) approved the 105 study.

106

107 Procedure and measurements

Using an ESM setup, this study set out to examine daily fluctuations of and associations between affect and post-COVID-19 symptom severity. Data were collected between September 5 and October 27, 2021, using the Ethica platform (ethicadata.com) and the related Ethica smartphone application. ESM data consisted of daily questionnaires on symptoms, feelings, and behaviours. Additional data were collected, but were beyond the scope of this study and are discussed elsewhere [25]. See Appendix S1 for the complete questionnaires in Dutch (original) and English (translated). Demographic and health-related characteristics were retrieved from hospital medical records with participants' approval.

Participants were followed for 14 consecutive days via seven daily self-report questionnaires prompted by a beep signal, of which six were relevant for this study. These short questionnaires – taking approximately two minutes – were prompted semi-randomly within two-hour intervals at 08.00 - 09.59, 10.00 - 11.59, 12.00 - 13.59, 14.00 - 15.59, 16.00 - 17.59, and 18.00 - 19.59 (i.e. signal-contingent sampling). Each notification expired after 15 minutes to prevent reactivity (i.e. participants 'preparing themselves' for the prompts) without being too inconvenient [23, 26].

Affect and Post-COVID-19 Symptoms in Daily Life

121 The questionnaires assessed, in fixed order, symptom severity and affect. Fatigue – assessed as 122 physical fatigue and mental fatigue – and dyspnoea were observed real-time using statements ("right 123 now, I feel shortness of breath") that could be answered using 7-point Likert-type answers: 1 – 'strongly 124 disagree' to 7 – 'strongly agree'. Cognitive function was assessed by asking for clarity of thought ("how is your 'thinking' (concentration, memory, attention) right now?") on a visual analogue scale (VAS): 0 125 - 'slow and difficult' to 10 - 'sharp and alert'. This scale was reversed for analysis (cognitive 126 127 dysfunction), so that higher scores indicated higher severity. Pain was assessed first by asking if the 128 participant experienced pain 'right now' (presence of pain). If affirmative, four additional prompts 129 opened up to assess the severity of headache, joint pain, chest pain, and pain 'elsewhere in the body' or 130 non-specific, which could be answered on four VAS: 0 -'no pain' to 10 -'worst imaginable pain'. 131 However, as these pains varied too much between participants, the VAS were omitted from further 132 analysis. Nevertheless, their pain courses over time per participant were visualised and are reported in 133 Appendix S4. Affect was assessed using statements on five negative (anxious, gloomy, sad, irritable, 134 and disappointed) and five positive feelings (excited, relaxed, satisfied, thankful, and joyful; e.g. "right 135 now, I feel satisfied"), to be answered on a 7-point Likert-type scale: 1 - 'strongly disagree' to 7 -136 'strongly agree'. Two mean scales of the five positive affect items and five negative affect items were 137 created as intercorrelations within these constructs were very high (both: Cronbach's $\alpha = .96$). 138 Additionally, a categorical variable (affect category) was made to indicate whether participants were 139 predominantly positive (positive affect >4), predominantly negative (negative affect >4) or neither predominantly positive nor negative ('neutral'). All items were based on previously validated 140 141 questionnaires or ESM studies [27-34].

142

Data analysis 143

144 ESM data consisted of observations (level 1) within days (level 2) within individuals (level 3). To make full use of the richness of these observations, data were primarily assessed visually. 145 Observations were plotted for exploration per participant (affect and symptoms), per symptom by affect 146

Affect and Post-COVID-19 Symptoms in Daily Life

- 147 category, and per symptom at the current time (t) with affect category of the previous time point (lagged
- 148 t-1). The graphs were plotted in RStudio version 23.03.0 +386 [35].

149 Additionally, statistical models were used to support these interpretations. Statistical evidence 150 for associations between symptoms were explored using personal averages (Person Mean) of each 151 participant to account for potential within-person fluctuations. Spearman rank correlations (r_s) were used 152 to account for non-parametric distributions and the small sample size. To assess potential associations 153 between affect and symptoms structured as two levels (observations nested within participants), 154 multilevel linear regression (MLR) models via the SPSS MIXED procedure were used. These models 155 also account for randomly missing observations, which is common in ESM studies. The models 156 accounted for participants (subjects) and timepoints (repeated measures), and were set up with restricted 157 maximum likelihood estimations and first-order autoregressive (AR1) covariance structure, which was 158 found to be best fitting according to the Akaike Information Criterion (AIC). As variables were 159 measured with different scales, Z-scores were used for analysis and to retrieve standardised regression 160 estimates. In the concurrent MLR models, each symptom was the outcome variable with either positive 161 affect or negative affect as the fixed covariate. Due to a strong correlation between positive affect and 162 negative affect ($r_s = -.82$), these variables were examined separately in univariate MLR. To examine the 163 prospective associations, positive and negative affect were lagged to the previous timepoint (t-1) in 164 relation to the timepoint of the symptom. For these models, each first symptom measurement of the day 165 was omitted, as the time between prior affect and symptom was too long (e.g. affect at T6 (e.g. 18.30) 166 was adjusted to not predict an effect on fatigue next day at T7 (08.30)). Additionally, the outcome symptom was lagged t-1 and added as fixed covariate, to adjust for a continuance or residual experience 167 168 of the symptom. Statistical significance was assessed using 95% confidence intervals and $\alpha < .05$. 169 Standardised regression estimates were interpreted as small (>.1), medium (>.3) or large (>.5) effect 170 size following Cohen's guidelines [36]. Descriptive statistics are presented in absolute number and 171 percentages or median (Mdn) and interquartile range (IOR). IBM SPSS Statistics 28 was used for all 172 statistical analyses.

173

Affect and Post-COVID-19 Symptoms in Daily Life

174 **Results**

Sample characteristics

After removing one participant with a compliance rate <30%, the final sample comprised 10 participants, who were between 48 and 76 (*Mdn* = 60, *IQR* = 9) years old and half of whom were women (*n* = 5). Five participants had one comorbidity, three participants had two or more and two had no comorbidities. All but two participants (80%) were overweight (Body Mass Index ≥ 25 ; *Mdn* = 29.0, *IQR* = 14.6, *Min* = 22.0, *Max* = 41.8). Observations were made between 8 and 12 (*Mdn* = 10, *IQR* = 2) months after hospital discharge. Compliance rates of participants varied between 32 and 92% (*Mdn* = 63.5%, *IQR* = 40.1%), with in total 502 completed questionnaires.

183

184 Courses of post-COVID symptoms and affect

185 Visual assessment of the daily average symptom severity per participant (Fig 1) suggested that 186 there were clear between-person differences in experiences of symptoms. Furthermore, physical and 187 mental fatigue, dyspnoea and, to a lesser extent, cognitive dysfunction associated with each other over 188 time on a daily level: an increase in one symptom co-occurred with an increase in the other. This 189 interpretation was supported by correlational analyses of person mean severities (r_s between .37 and .85, 190 p < .001; Table 1). For example, if a participant tends to experience physical fatigue, they also tend to 191 experience cognitive dysfunction ($r_s(8) = .80$, p < .001). Although less obvious from the visual 192 assessment, presence of pain likewise was weakly to moderately correlated to higher severity of other 193 symptoms (r_s between .26 and .54, p < .001; Table 1). Visual assessment of the graphs (see Fig 2 for the 194 course of physical fatigue per participant; see S2 for courses of mental fatigue, cognitive dysfunction, 195 dyspnoea and pain per participant) revealed that symptoms fluctuated over time to various degrees. 196 Cognitive dysfunction and pain showed the least variability and were mostly stable within participants. 197 Aside from that, no clear temporal patterns were observed within participants. To illustrate, while 198 physical fatigue often was lower in the afternoon for participant B, this was not necessarily the case 199 every day (Fig 2).

Affect and Post-COVID-19 Symptoms in Daily Life

200 Fig 1. Daily average symptom severity over 14 days for participants A - J. Pain presence was a

201 dichotomous variable, with 1 = present and 0 = absent. Consequently, scores of e.g. 0.8 indicate that a

- 202 participant did mostly but not always experience pain that day. See Fig 2 and Appendix S2 for more
- 203 detailed insights in symptom courses.
- 204 Fig 2. Course of physical fatigue over 14 days with corresponding affect per participant A - J.

205

206 Table 1. Spearman correlations between symptoms at person mean level.

	Physical	Mental	Cognitive	
	fatigue	fatigue	dysfunction	Dyspnoea
Physical fatigue	-			
Mental fatigue	.76***	-		
Cognitive dysfunction	.73***	.37***	-	
Dyspnoea	.88***	.53***	.66***	-
Pain presence	.25***	.32***	.27***	.37***

207

 $^{***} = p < .001.$

208

209 Affect was mostly stable within participants, with two participants (C and I, Fig 2; see S4 for 210 courses of and interrelations between positive and negative affect per participant) predominantly 211 experiencing negative affect. No evidence for emotional instability was found (S4).

212

Associations between affect and post-COVID symptoms 213

Concurrent associations 214

215 Overall, negative affect co-occurred with higher severity in all symptoms (Fig 2 and S2). 216 Additionally, experiencing neither predominantly positive nor negative ('neutral') affect co-occurred 217 with higher symptom severity. Conversely, predominantly positive affect co-occurred more often with

Affect and Post-COVID-19 Symptoms in Daily Life

218	lower symptom severity. Pain seemed to be present regardless of affective tendencies in most
219	participants. MLR models (Table 2) supported these assessments for all associations, and seem to
220	suggest that both affects influence symptoms to a similar extent. For example, cognitive dysfunction
221	was (almost) strongly and significantly associated negatively with positive affect ($\beta =46$) and
222	positively with negative affect ($\beta = .51$).

223

224 Table 2. Overview of 10 univariate models of positive and negative affect as concurrent predictors

225 of symptoms.

Outcome	Positive affect			Negative affect			
	ß	SE	95%CI	ß	SE	95%CI	
Physical fatigue	67	0.04	75 to59	.59	0.05	.49 to .69	
Mental fatigue	59	0.05	69 to49	.66	0.05	.56 to .76	
Cognitive dysfunction	46	0.05	55 to36	.51	0.06	.39 to .62	
Dyspnoea	49	0.05	60 to39	.37	0.07	.24 to .50	
Pain presence	28	0.06	39 to16	.24	0.07	.10 to .38	

Standardised estimates of fixed covariate (either positive or negative affect) on outcome (symptom) in 226 227 univariate multilevel linear regression models. All associations were statistically significant, p < .001. SE = standard error; 95%CI = 95% confidence intervals presented with respectively lower and upper 228 229 limits.

230

Time-lagged associations 231

232 To explore whether symptoms were influenced by affect, positive and negative affect were lagged to the prior observation (t-1; visualisations in S3). As affect was relatively stable within 233 participants, influences are inconclusive, but a change from positive to 'neutral' or negative affect might 234 indicate a worsening of symptom severity (see e.g. Participant A). MLR models showed that although 235 236 symptom severity often was a continuance or remnant of previous measurement – especially for the 237 more stable symptoms such as cognitive dysfunction and presence of pain – both positive and negative

Affect and Post-COVID-19 Symptoms in Daily Life

- affect still were significant but mostly weak predictors (Table 3), suggesting a small influence of affect 238
- 239 on symptoms two hours later. Post-hoc analyses showed that, in line with the stable affect trajectories,
- 240 time-lagged symptoms were not significant predictors of positive and negative affect two hours later.
- 241
- 242 Table 3. Overview of 10 multivariate models of positive and negative affect as time-lagged
- 243 predictors of symptoms.

Outcome	Predictor	Positive affect			Negative affect		
		ß	SE	95%CI	ß	SE	95%CI
Physical fatigue	Affect t-1	31	0.05	41 to20	.27	0.05	.17 to .36
	Physical fatigue t-1	.46	0.05	.36 to .57	.51	0.05	.41 to .60
Mental fatigue	Affect t-1	18	0. 05	27 to08	.28	0.05	.19 to .38
	Mental fatigue t-1	.65	0. 05	.56 to .74	.54	0.05	.45 to .64
Cognitive	Affect t-1	14	0.04	21 to07	.12	0.03	.06 to .19
dysfunction	Cognitive dysfunction t-1	.82	0.04	.75 to .89	.85	0.03	.78 to .91
Dyspnoea	Affect t-1	22	0.04	31 to14	.18	0.04	.10 to .26
	Shortness of t-1	.61	0.05	.52 to .71	.67	0.04	.58 to .75
Pain presence	Affect t-1	09†	0.03	15 to03	.09†	0.03	.03 to .15
	Pain t-1	.82	0.03	.76 to .89	.83	0.03	.76 to .90

244 Standardised estimates of fixed covariates (residual symptom and (either positive or negative) affect) 245 on outcome (symptom) in multivariate multilevel linear regression models. The first preceding measurement of each predictor is represented as t-1. All associations were statistically significant at p 246 247 <.001, except for [†]: p = .006. SE = standard error; 95%CI = 95% confidence intervals presented with 248 respectively lower and upper limits.

Affect and Post-COVID-19 Symptoms in Daily Life

249 **Discussion**

This study explored the daily courses of and interrelations between affect and post-COVID-19 symptoms using an ESM approach. The main finding was that both positive and negative affect predicted symptom severity both concurrently and two hours later. Moreover, post-COVID-19 symptoms were found to fluctuate in severity both within and between days, and these severities fluctuated in co-occurrence with each other.

255 This study showed that affect might play a role in the experience of post-COVID-19 symptom 256 severity. This finding is in line with expectations that symptom severity is reduced in occurrence with 257 and after positive affect, which is based on the Broaden-and-Build framework [14]. Moreover, the 258 results are in accordance with previous findings on the relationships between trait affect and fatigue, 259 dyspnoea and pain in other patient populations [17, 20, 21, 37]. Furthermore, they are comparable to 260 findings in functional somatic syndromes such as fibromyalgia and chronic fatigue syndrome. For these 261 syndromes, it has been reported that negative affective states and negative trait affect elicit increased 262 symptom severity [22, 38], and that positive trait affect was associated with decreased symptom severity 263 [22]. The present study suggests that similar affect – symptom relationships also exist in post-COVID-19 patients, and adds to the understanding that these relationships occur on a momentary level and have 264 265 short-term persisting effects by showing that small to medium effects of positive and negative affect on 266 symptoms can also be observed two hours later.

Based on visual assessment, a difference in the relationship of positive and negative affect with 267 268 symptom severity was observed. Negative affect was mostly consistent within two participants, while 269 positive affect fluctuated more often and co-occurred with fluctuating symptom severity. This might 270 suggest that there are important between- and within-individual differences. Previous findings in a 271 general population showed that relationships between affect and somatic symptoms are better explained 272 on a between-individual level by negative affect and on a within-individual level by positive affect [39]. 273 Consequently, future studies on the relationships between affect or psychological issues (such as 274 depression, anxiety or uncertainty) and post-COVID-19 symptoms should account for within-individual 275 differences that may be obscured by between-individual findings. Moreover, for treatment, this indicates

Affect and Post-COVID-19 Symptoms in Daily Life

276 that different (affect-related) psychological approaches might be necessary and promising when dealing

277 with symptom (self-)management.

278 Results also showed between- and within-individual differences in symptom severity. Not all 279 participants experienced the same symptoms, and did not experience these symptoms at similar times. 280 Moreover, no clear temporal trajectories could be observed in patients who experienced certain 281 symptoms. For example, participants either experienced always severe or no dyspnoea, or the severity 282 fluctuated for - as of yet - undetermined reasons (S2). Aside from small influences of affect, these 283 fluctuations may be partially explained by exertion and daily activities, as previously explored for 284 physical and mental fatigue in this sample [25].

285 Overall, present symptoms seemed to mostly co-occur, as they associated positively with each 286 other over time within this sample- especially within somatic symptoms. Previously, it was shown using 287 cross-sectional measures that many post-COVID-19 patients experience multiple symptoms (e.g. 288 combinations of fatigue and pain, respiratory issues, and cognitive problems) at the same time, adding 289 to the experienced disease burden [3]. The current study adds to the understanding that symptoms might 290 influence each other's severity. Interestingly, these associations could also be beneficial for patients, as 291 it suggests that successfully targeting one symptom (e.g. dyspnoea) for an intervention might also result 292 in a reduction in other symptoms (e.g. physical fatigue and pain). Although the present study cannot 293 provide full evidence for this, these general trends may indicate that in accordance with the Broaden-294 and-Build framework and previous empirical findings that investigated sum score measures of 295 symptoms [e.g., 39, 40], an overall increased well-being might similarly result in an overall decrease in 296 symptom severity.

297 Taken together, our findings, especially on the role of positive affect, may serve as ground for 298 exploration of an affect-based intervention, such as a positive psychological intervention (PPI). PPI have 299 been found to be effective especially in chronic pain management and self-regulation [41, 42], and in 300 reducing distress [43]. Therefore, they seem useful for post-COVID-19 symptom management. 301 Additionally, an advantage of PPI is that they may provide participants with a sense of control over their 302 rehabilitation. Perceived control was found to be severely impacted in post-COVID-19 patients [13]. 303 Moreover, the effects of PPI are quickly noticeable by participants [see e.g. 44]. To make best use of

Affect and Post-COVID-19 Symptoms in Daily Life

304 these interventions, tailoring to participants' needs might be necessary. Given the temporal association 305 between (positive) affect and symptom severity, tailored adaptive interventions that identify specific 306 times at which PPI could best take place (e.g. just-in-time adaptive interventions) seem promising. 307 Future studies should explore the best targets for these times, or whether these interventions should even 308 be time-based.

309 The strength of this study is the experience sampling methodology, which allowed for an in-310 depth exploration of real-time assessed affect and symptom severity, increasing the reliability and 311 ecological validity [23]. Moreover, by plotting participants' individual experiences of affect and 312 symptoms over the day, a deep understanding was gained. Although this analytical strategy compensated 313 for the small sample, the sample size can be seen as a limitation. Care should be taken to generalise the 314 results. Evidence for temporal symptom patterns and stronger affect variability or instability may have 315 arisen in a larger sample. Moreover, while the number of observations included was high, an average 316 response rate of 60% is – while acceptable for ESM studies [23, 26] – rather low. Additionally, the 317 sample was mostly homogeneous and consisted of patients with a relatively long course of post-COVID-318 19 syndrome following COVID-19 hospitalisation. Participants may have already learnt to live with 319 their illness, as well as how to deal with certain negative emotions. Consequently, more recently 320 diagnosed patients may experience more negative affect or higher symptom severity. Similarly, the 321 effects of (the number of) vaccinations have not been accounted for. These have been shown to produce 322 certain ameliorating effects on post-COVID-19 syndrome [45].

323

Conclusions 324

325 This study used an Experience Sampling Methodology to assess the temporal courses of and 326 relations between affect and symptoms in the post-COVID-19 patients. It provided important insights 327 in the momentary and prospective interactions between affect and post-COVID-19 symptoms. Both 328 positive and negative affect play small but important roles in the severity of fatigue, cognitive 329 dysfunction and dyspnoea and the presence of pain. Future studies should replicate and further explore

Affect and Post-COVID-19 Symptoms in Daily Life

- these associations in large and more diverse samples, to use insights for advanced psychological
- 331 interventions for post-COVID-19 patients.
- 332

333 Acknowledgements

334 The authors thank Peter ten Klooster for his advice and support in data management and the statistical

- analyses.
- 336

337 **References**

- 1. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the
- long-term effects of COVID-19 2021 [updated November 11; cited 2023 May 22]. Available from:
- 340 <u>https://www.nice.org.uk/guidance/ng188</u>.
- 2. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of
- 342 Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and

343 Systematic Review. J Infect Dis. 2022;226(9):1593-607. doi: 10.1093/infdis/jiac136. PubMed PMID:

344 35429399; PubMed Central PMCID: PMCPMC9047189.

345 3. Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of

346 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following

347 Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-15. doi:

- 348 10.1001/jama.2022.18931.
- 349 4. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence

and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A

351 systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. Epub 20221201. doi:

352 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID:

353 PMCPMC9714474.

5. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et

al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv.

It is made available under a CC-BY 4.0 International lice Affect and Post-COVID-19 Symptoms in Daily Life

- 356 2021. Epub 2021/02/04. doi: 10.1101/2021.01.27.21250617. PubMed PMID: 33532785; PubMed
- 357 Central PMCID: PMCPMC7852236 Company; the statements presented in the paper do not
- necessarily represent the position of the company. The remaining authors have no competing intereststo declare.
- 360 6. Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19
- 361 syndrome (PCS) and health-related quality of life (HRQoL)—A systematic review and meta-analysis.
- 362 J Med Virol. 2022;94(1):253-62. doi: 10.1002/jmv.27309.
- 363 7. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and
- 364 symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract.

365 2021;75(10):e14357-e. Epub 2021/06/02. doi: 10.1111/ijcp.14357. PubMed PMID: 33977626.

- 366 8. Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al.
- 367 Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living

368 systematic review. medRxiv. 2021:2021.06.03.21258317. doi: 10.1101/2021.06.03.21258317.

- 369 9. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising
- 370 long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. doi: 10.1136/bmjgh-
- 371 2021-005427. PubMed PMID: 34580069.
- 10. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms
- after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services.
- 374 BMC Health Serv Res. 2020;20(1):1144. Epub 2020/12/22. doi: 10.1186/s12913-020-06001-y.
- PubMed PMID: 33342437; PubMed Central PMCID: PMCPMC7750006.

Buttery S, Philip KEJ, Williams P, Fallas A, West B, Cumella A, et al. Patient symptoms and
experience following COVID-19: Results from a UK-wide survey. BMJ Open Respiratory Research.

- 378 2021;8(1). doi: 10.1136/bmjresp-2021-001075.
- 12. Humphreys H, Kilby L, Kudiersky N, Copeland R. Long COVID and the role of physical
- 380 activity: a qualitative study. BMJ Open. 2021;11(3):e047632. doi: 10.1136/bmjopen-2020-047632.
- 381 13. Schaap G, Wensink M, Doggen CJM, van der Palen J, Vonkeman HE, Bode C. "It Really Is
- an Elusive Illness"- Post-COVID-19 Illness Perceptions and Recovery Strategies: A Thematic
- 383 Analysis. Int J Environ Public Health. 2022;19(20):13003. doi: 10.3390/ijerph192013003.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298760; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Affect and Post-COVID-19 Symptoms in Daily Life

- 384 14. Fredrickson BL. The role of positive emotions in positive psychology. The broaden-and-build
- 385 theory of positive emotions. Am Psychol. 2001;56(3):218-26. doi: 10.1037//0003-066x.56.3.218.
- 386 PubMed PMID: 11315248; PubMed Central PMCID: PMCPMC3122271.
- 387 15. Fredrickson BL. The broaden-and-build theory of positive emotions. Philosophical
- 388 Transactions of the Royal Society of London Series B: Biological Sciences. 2004;359(1449):1367-77.
- doi: 10.1098/rstb.2004.1512.
- 390 16. Frijda NH. The emotions. Paris, France: Editions de la Maison des Sciences de l'Homme;
- 391 1986. xii, 544-xii, p.
- 392 17. von Leupoldt A, Denutte Y. Affective traits, states, and breathlessness. Curr Opin Support

393 Palliat Care. 2020;14(3):182-9. doi: 10.1097/spc.000000000000506. PubMed PMID: 01263393-

- 394 202009000-00006.
- 395 18. Finan PH, Garland EL. The role of positive affect in pain and its treatment. Clin J Pain.
- 396 2015;31(2):177-87. doi: 10.1097/AJP.000000000000092.
- 19. Hanssen MM, Peters ML, Boselie JJ, Meulders A. Can positive affect attenuate (persistent)
- 398 pain? State of the art and clinical implications. Current Rheumatology Reports. 2017;19(12):80. doi:
- 399 10.1007/s11926-017-0703-3.
- 400 20. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, Reid MC. Positive affect and chronic
- 401 pain: a preregistered systematic review and meta-analysis. PAIN. 2020;161(6):1140-9. doi:
- 402 10.1097/j.pain.00000000001828. PubMed PMID: 00006396-202006000-00004.
- 403 21. Strebkova R. Subjective Well-Being and its Impact on Cancer-Related Fatigue in Patients
- 404 Undergoing Radiotherapy and Long-Term Survivors. Acta Medica Bulgarica. 2020;47(4):18-23. doi:
- 405 doi:10.2478/amb-2020-0040.
- 406 22. Toussaint LL, Vincent A, McAllister SJ, Oh TH, Hassett AL. A comparison of fibromyalgia
- 407 symptoms in patients with Healthy versus Depressive, Low and Reactive affect balance styles. Scand J
- 408 Pain. 2014;5(3):161-6. doi: 10.1016/j.sjpain.2014.05.001.
- 409 23. Myin-Germeys I, Kuppens P, editors. The open handbook of experience sampling
- 410 methodology: A step-by-step guide to designing, conducting, and analyzing ESM studies. 2nd ed.
- 411 Leuven: Center for Research on Experience Sampling and Ambulatory Methods Leuven; 2022.

Affect and Post-COVID-19 Symptoms in Daily Life

412 24. Aaronson NK, Muller M, Cohen PDA, Essink-Bot M-L, Fekkes M, Sanderman R, et al.

Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in 413

414 Community and Chronic Disease Populations. J Clin Epidemiol. 1998;51(11):1055-68. doi:

415 10.1016/S0895-4356(98)00097-3.

Wensink M, Schaap G, ten Klooster PM, Doggen CJM, van der Palen J, Vonkeman HE, et al. 416 25.

417 Physical and mental fatigue in post-COVID syndrome and their associations over time: A small-

sample ESM-study to explore fatigue, quality of sleep and behaviours. J Psychosom Res. 418

419 2023;164:111084. doi: https://doi.org/10.1016/j.jpsychores.2022.111084.

420 26. Conner TS, Lehman BJ. Launching a Study in Daily Life. In: Mehl M, Conner TS, editors.

421 Handbook of Research Methods for Studying Daily Life. New York: Guilford Press; 2012. p. 88 - 107.

422 27. Brys ADH, Stifft F, Van Heugten CM, Bossola M, Gambaro G, Lenaert B. Unraveling Fatigue

423 in Hemodialysis Patients: Comparing Retrospective Reports to Real-Time Assessments With an

424 mHealth Experienced Sampling Method. J Pain Symptom Manage. 2020;60(6):1100-8.e2. doi:

425 10.1016/j.jpainsymman.2020.06.042.

426 28. Dietvorst E, Hiemstra M, Maciejewski D, van Roekel E, Bogt Tt, Hillegers M, et al. Grumpy

427 or depressed? Disentangling typically developing adolescent mood from prodromal depression using

428 experience sampling methods. J Adolesc. 2021;88:25-35. doi: 10.1016/j.adolescence.2021.01.009.

429 29. Jean FAM, Sibon I, Husky M, Couffinhal T, Swendsen J. Feasibility and validity of

430 Ecological Momentary Assessment in patients with acute coronary syndrome. BMC Cardiovasc

431 Disord. 2020;20(1). doi: 10.1186/s12872-020-01774-w.

432 30. Kratz AL, Braley TJ, Foxen-Craft E, Scott E, Murphy JF, Murphy SL. How Do Pain, Fatigue,

433 Depressive, and Cognitive Symptoms Relate to Well-Being and Social and Physical Functioning in the

434 Daily Lives of Individuals With Multiple Sclerosis? Arch Phys Med Rehabil. 2017;98(11):2160-6.

435 doi: 10.1016/j.apmr.2017.07.004.

436 31. Lenaert B. Neijmeijer M. van Kampen N. van Heugten C. Ponds R. Poststroke Fatigue and

Daily Activity Patterns During Outpatient Rehabilitation: An Experience Sampling Method Study. 437

Arch Phys Med Rehabil. 2020;101(6):1001-8. doi: 10.1016/j.apmr.2019.12.014. PubMed PMID: 438

439 WOS:000543030600008.

It is made available under a CC-BY 4.0 International licens Affect and Post-COVID-19 Symptoms in Daily Life

- 440 32. Maes IHL, Delespaul PAEG, Peters ML, White MP, van Horn Y, Schruers K, et al. Measuring
- 441 Health-Related Quality of Life by Experiences: The Experience Sampling Method. Value Health.
- 442 2015;18(1):44-51. doi: 10.1016/j.jval.2014.10.003.
- 443 33. Romano KA, Heron KE, Smith KE, Crosby RD, Engel SG, Wonderlich SA, et al. Somatic
- 444 symptoms and binge eating in women's daily lives. J Psychosom Res. 2020;135. doi:
- 445 10.1016/j.jpsychores.2020.110161.
- 446 34. Worm-Smeitink M, Monden R, Groen RN, van Gils A, Bekhuis E, Rosmalen J, et al. Towards
- 447 personalized assessment of fatigue perpetuating factors in patients with chronic fatigue syndrome
- 448 using ecological momentary assessment: A pilot study. J Psychosom Res. 2021;140. doi:
- 449 10.1016/j.jpsychores.2020.110296.
- 450 35. Posit Team. RStudio: Integrated Development Environment for R: Posit Software, PBC; 2023.
- 451 Available from: <u>https://posit.co/</u>.
- 452 36. Cohen J. Statistical Power Analysis for the Behavioural Sciences: Academic Press, New York;
 453 1988.
- 454 37. Zautra AJ, Fasman R, Parish BP, Davis MC. Daily fatigue in women with osteoarthritis,
- 455 rheumatoid arthritis, and fibromyalgia. Pain. 2007;128(1):128-35. doi: 10.1016/j.pain.2006.09.004.
- 456 38. Van Den Houte M, Bogaerts K, Van Diest I, De Bie J, Persoons P, Van Oudenhove L, et al.
- 457 Inducing Somatic Symptoms in Functional Syndrome Patients: Effects of Manipulating State Negative
- 458 Affect. Psychosom Med. 2017;79(9):1000-7. doi: 10.1097/psy.000000000000527. PubMed PMID:
- 459 00006842-201711000-00007.
- 460 39. Schenk HM, Bos EH, Slaets JPJ, de Jonge P, Rosmalen JGM. Differential association between
- 461 affect and somatic symptoms at the between- and within-individual level. Br J Health Psychol.
- 462 2017;22(2):270-80. doi: 10.1111/bjhp.12229.
- 463 40. Clark LA, Watson D. Mood and the mundane: relations between daily life events and self-
- reported mood. J Pers Soc Psychol. 1988;54(2):296-308. doi: 10.1037//0022-3514.54.2.296. PubMed
 PMID: 3346815.


Affect and Post-COVID-19 Symptoms in Daily Life

- 41. Braunwalder C, Müller R, Glisic M, Fekete C. Are Positive Psychology Interventions 466
- 467 Efficacious in Chronic Pain Treatment? A Systematic Review and Meta-Analysis of Randomized
- 468 Controlled Trials. Pain Med. 2021;23(1):122-36. doi: 10.1093/pm/pnab247.
- 469 42. Iddon JE, Dickson JM, Unwin J. Positive Psychological Interventions and Chronic Non-
- Cancer Pain: A Systematic Review of the Literature. Int J Appl Posit Psychol. 2016;1(1):133-57. doi: 470
- 471 10.1007/s41042-016-0003-6.
- 472 43. Chakhssi F, Kraiss JT, Sommers-Spijkerman M, Bohlmeijer ET. The effect of positive
- 473 psychology interventions on well-being and distress in clinical samples with psychiatric or somatic
- 474 disorders: a systematic review and meta-analysis. BMC Psychiatry. 2018;18(1):211. Epub 20180627.
- 475 doi: 10.1186/s12888-018-1739-2. PubMed PMID: 29945603; PubMed Central PMCID:
- 476 PMCPMC6020379.
- 477 Geschwind N, Arntz A, Bannink F, Peeters F. Positive cognitive behavior therapy in the 44.
- 478 treatment of depression: A randomized order within-subject comparison with traditional cognitive
- 479 behavior therapy. Behav Res Ther. 2019;116:119-30. Epub 20190309. doi:
- 480 10.1016/j.brat.2019.03.005. PubMed PMID: 30897464.
- 45. 481 Tofarides AG, Christaki E, Milionis H, Nikolopoulos GK. Effect of Vaccination against
- SARS-CoV-2 on Long COVID-19: A Narrative Review. Life (Basel). 2022;12(12). Epub 20221208. 482
- 483 doi: 10.3390/life12122057. PubMed PMID: 36556422; PubMed Central PMCID: PMCPMC9785763.

484


Supporting information 485

- 486 **S1.** Morning and momentary questionnaires
- 487 S2. Visualisations of courses of symptoms with concurrent affect
- 488 S3. Visualisations of courses of symptoms with time-lagged affect
- 489 S4. Visualisations of courses of affect and of specified pains



Symptoms 🔹 Physical Fatigue 🔹 Mental Fatigue 😁 Cognitive Dystunction 😁 Dysproea 🛥 Presence of Pain

Fig 1



\$\$\$\$\$\$\$\$\$ 0.0.0.0.0.000 0.0.0.00000 0.000000000 0.00 a. 0,00 6600 0,000 00 6666 66666

Moment of the Day